Prognostic correlation of cell cycle progression score and Ki-67 as a predictor of aggressiveness, biochemical failure, and mortality in men with high-risk prostate cancer treated with external beam radiation therapy

Publication date: May–June 2017
Source:Reports of Practical Oncology & Radiotherapy, Volume 22, Issue 3
Author(s): Iván Henríquez López, David Parada, Pablo Gallardo, Marina Gascón, Arnau Besora, Karla Peña, Francesc Riu, Miquel Arquez Pianetta, Oscar Abuchaibe, Laura Torres Royò, Meritxell Arenas
ObjectivesKi-67 is a proliferation marker in prostate cancer. A prognostic RNA signature was developed to characterize prostate cancer aggressiveness.The aim was to evaluate prognostic correlation of CCP and Ki-67 with biochemical failure (BF), and survival in high-risk prostate cancer patients (pts) treated with radiation therapy (RT).MethodsCCP score and Ki-67 were derived retrospectively from pre-treatment paraffin-embedded prostate cancer tissue of 33 men diagnosed from 2002 to 2006.CCP score was calculated as an average expression of 31 CCP genes. Ki-67 was determined by IHC. Single pathologist evaluated all tissues. Factors associated to failure and survival were analyzed.ResultsMedian CCP score was 0.9 (-0-1 – 2.6). CCP 0: 1 pt; CCP 1: 19 pts; CCP 2: 13 pts. Median Ki-67 was 8.9. Ki-67 cutpoint was 15.08%.BF and DSM were observed in 21% and 9%. Ki-67≥15% predicted BF (p=0.043). With a median follow-up of 8.4 years, 10-year BF, OS, DM and DSM for CCP 1 vs. CCP 2 was 76–71% (p=0.83), 83–73% (p=0.86), 89–85% (p=0.84), and 94–78% (p=0.66).On univariate, high Ki-67 was correlated with BF (p=0.013), OS (p=0.023), DM (p=0.007), and DSM (p=0.01). On Cox MVA, high Ki-67 had a BF trend (p=0.063). High CCP score was not correlated with DSM.ConclusionsHigh Ki-67 significantly predicted outcome and provided prognostic information. CCP score may improve accuracy stratification. We did not provide prognostic correlation of CCP and DSM. It should be validated in a larger cohort of pts.



http://ift.tt/2q6zbfP